Relative Addictive Potential of Opioid Analgesic Agents

References

• U.S. National Institute on Drug Abuse . Overdose death rates. www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
   Google Scholar
• Scholl L , SethP , KariisaM , WilsonN , BaldwinG. Drug and opioid-involved overdose deaths – United States, 2013–2017. MMWR Morb. Mortal. Wkly Rep.67(5152), 1419–1427 (2018).
   PubMedGoogle Scholar
• Shah A , HayesCJ , MartinBC. Characteristics of initial prescription episodes and likelihood of long-term opioid use – United States, 2006–2015. MMWR Morb. Mortal. Wkly Rep.66(10), 265–269 (2017).
   PubMedGoogle Scholar
• Koob GF , VolkowND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psych.3(8), 760–773 (2016).
   PubMed Web of Science ®Google Scholar
• Horseman C , MeyerA. Neurobiology of addiction. Clin. Obstet. Gynecol.62(1), 118–127 (2019).
   PubMed Web of Science ®Google Scholar
• Feltenstein MW , SeeRE. Systems level neuroplasticity in drug addiction. Cold Spring Harb. Perspect. Med.3(5), a011916 (2013).
   PubMed Web of Science ®Google Scholar
• Volkow ND , FowlerJS , WangGJ. The addicted human brain: insights from imaging studies. J. Clin. Invest.111(10), 1444–1451 (2003).
   PubMed Web of Science ®Google Scholar
• Caine SB , ThomsenM , GabrielKIet al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J. Neurosci.27(48), 13140–13150 (2007).
   PubMed Web of Science ®Google Scholar
• Robbins TW . Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. Nature264(5581), 57–59 (1976).
   PubMed Web of Science ®Google Scholar
• Waldhoer M , BartlettSE , WhistlerJL. Opioid receptors. Annu. Rev. Biochem.73, 953–990 (2004).
   PubMed Web of Science ®Google Scholar
• Roden DM , McLeodHL , RellingMVet al. Pharmacogenomics. Lancet394(10197), 521–532 (2019).
   PubMed Web of Science ®Google Scholar
• Relling MV , EvansWE. Pharmacogenomics in the clinic. Nature526(7573), 343–350 (2015).
   PubMed Web of Science ®Google Scholar
• Smith HS . Opioid metabolism. Mayo Clinic Proc.84(7), 613–624 (2009).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M . Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn. Schmiedebergs. Arch. Pharmacol.369(1), 89–104 (2004).
   PubMed Web of Science ®Google Scholar
• Mcgraw J , WallerD. Cytochrome P450 variations in different ethnic populations. Expert Opin. Drug Metab. Toxicol.8(3), 371–382 (2012).
   PubMed Web of Science ®Google Scholar
• Depriest AZ , PuetBL , HoltAC , RobertsA , ConeEJ. Metabolism and disposition of prescription opioids: a review. Forensic Sci. Rev.27(2), 115–145 (2015).
   PubMedGoogle Scholar
• Kiang TKL , EnsomMHH , ChangTKH. UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol. Ther.106(1), 97–132 (2005).
   PubMed Web of Science ®Google Scholar
• Lötsch J . Opioid metabolites. J. Pain Symptom Manage.29(Suppl. 5), S10–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Somogyi AA , BarrattDT , CollerJK. Pharmacogenetics of opioids. Clin. Pharmacol. Ther.81(3), 429–444 (2007).
   PubMed Web of Science ®Google Scholar
• Zanger UM , SchwabM. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities and impact of genetic variation. Pharmacol. Ther.138(1), 103–141 (2013).
   PubMed Web of Science ®Google Scholar
• Miotto K , ChoAK , KhalilMA , BlancoK , SasakiJD , RawsonR. Trends in tramadol: pharmacology, metabolism and misuse. Anesth. Analg.124(1), 44–51 (2017).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ , Von MoltkeLL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol.48(11), 1350–1355 (2008).
   PubMed Web of Science ®Google Scholar
• Lamba V , PanettaJC , StromS , SchuetzEG. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J. Pharmacol. Exp. Ther.332(3), 1088–1099 (2010).
   PubMed Web of Science ®Google Scholar
• Schmidt R , BaumannF , HanschmannH , GeisslerF , PreissR. Gender difference in ifosfamide metabolism by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet.26(3), 193–200 (2001).
   PubMed Web of Science ®Google Scholar
• Soldini D , ZwahlenH , GabuttiL , MarzoA , MaroneC. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur. J. Clin. Pharmacol.60(12), 859–864 (2005).
   PubMed Web of Science ®Google Scholar
• Wolbold R , KleinK , BurkOet al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology38(4), 978–988 (2003).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M . Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci.25(4), 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Glaeser H , DrescherS , EichelbaumM , FrommMF. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br. J. Clin. Pharmacol.59(2), 199–206 (2005).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J.5(1), 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou S-F . Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet.48(11), 689–723 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Dosari MS , Al-JenoobiFI , AlkharfyKMet al. High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians. Environ. Toxicol. Pharmacol.36(3), 1063–1067 (2013).
   PubMed Web of Science ®Google Scholar
• Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics3(2), 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , OscarsonM , MclellanRA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci.20(8), 342–349 (1999).
   PubMed Web of Science ®Google Scholar
• Khalaj Z , BaratiehZ , NikpourPet al. Distribution of polymorphism in the Middle Eastern region. J. Res. Med. Sci.24, 61 (2019).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R . Inheritance and drug response. N. Engl. J. Med.348(6), 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Beoris M , AmosWilson J , GarcesJA , LukowiakAA. CYP2D6 copy number distribution in the US population. Pharmacogenet. Genomics26(2), 96–99 (2016).
   PubMed Web of Science ®Google Scholar
• Bernard S , NevilleKA , NguyenAT , FlockhartDA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist11(2), 126–135 (2006).
   PubMed Web of Science ®Google Scholar
• Tredici ALD , DelTredici AL , MalhotraAet al. Frequency of CYP2D6 alleles including structural variants in the United States. Front. Pharmacol.9, 305 (2018).
   PubMed Web of Science ®Google Scholar
• Smolina K , WeymannD , MorganS , RossC , CarletonB. Association between regulatory advisories and codeine prescribing to postpartum women. JAMA313(18), 1861–1862 (2015).
   PubMed Web of Science ®Google Scholar
• US FDA . FDA Public Health Advisory: use of codeine 2007. www.e-lactancia.org/media/papers/CodeinaBF-FDA2007.pdf
   Google Scholar
• Guillemette C , LévesqueÉ , RouleauM. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin. Pharmacol. Ther.96(3), 324–339 (2014).
   PubMed Web of Science ®Google Scholar
• Kadiev E , PatelV , RadPet al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin. Drug Metab. Toxicol.4(1), 77–91 (2008).
   PubMed Web of Science ®Google Scholar
• Hu DG , MeechR , LuL , MckinnonRA , MackenziePI. Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter. Drug Metab. Dispos.42(5), 854–862 (2014).
   PubMed Web of Science ®Google Scholar
• Stingl JC , BartelsH , VivianiR , LehmannML , BrockmöllerJ. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol. Ther.141(1), 92–116 (2014).
   PubMed Web of Science ®Google Scholar
• Bhasker CR , MckinnonW , StoneAet al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics10(8), 679–685 (2000).
   PubMedGoogle Scholar
• Holthe M , RakvågTN , KlepstadPet al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J.3(1), 17–26 (2003).
   PubMed Web of Science ®Google Scholar
• Bastami S , GuptaA , ZackrissonA-L , AhlnerJ , OsmanA , UppugunduriS. Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption. Basic Clin. Pharmacol. Toxicol.115(5), 423–431 (2014).
   PubMed Web of Science ®Google Scholar
• Madadi P , RossCJD , HaydenMRet al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clin. Pharmacol. Ther.85(1), 31–35 (2009).
   PubMed Web of Science ®Google Scholar
• Sistonen J , MadadiP , RossCJet al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin. Pharmacol. Ther.91(4), 692–699 (2012).
   PubMed Web of Science ®Google Scholar
• Aasmundstad TA , StørsetP. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Human Exp. Toxicol.17(6), 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Ammon S , MarxC , BehrensCet al. Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers. BMC Clin. Pharmacol.2, 2 (2002).
   PubMedGoogle Scholar
• Hara Y , NakajimaM , MiyamotoK-I , YokoiT. Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab. Pharmacokinet.22(2), 103–112 (2007).
   PubMed Web of Science ®Google Scholar
• Joo J , KimY-W , WuZet al. Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS. Biopharm. Drug Dispos.36(4), 258–264 (2015).
   PubMed Web of Science ®Google Scholar
• Raungrut P , UchaipichatV , ElliotDJ , JanchaweeB , SomogyiAA , MinersJO. In vitro–in vivo extrapolation predicts drug–drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole and methadone in humans. J. Pharmacol. Exp. Ther.334(2), 609–618 (2010).
   PubMed Web of Science ®Google Scholar
• Takeda S , IshiiY , MackenziePIet al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol. Pharm. Bull.28(10), 2026–2027 (2005).
   PubMed Web of Science ®Google Scholar
• Takeda S , KitajimaY , IshiiYet al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab. Dispos.34(8), 1277–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Trescot AM , DattaS , LeeM , HansenH. Opioid pharmacology. Pain Phys.11(Suppl. 2), S133–S153 (2008).
   PubMed Web of Science ®Google Scholar
• Andrzejowski P , CarrollW. Codeine in paediatrics: pharmacology, prescribing and controversies. Arch. Dis. Child. Educ. Pract. Ed.101(3), 148–151 (2016).
   PubMed Web of Science ®Google Scholar
• Caraco Y , TateishiT , GuengerichFP , WoodAJ. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab. Dispos.24(7), 761–764 (1996).
   PubMed Web of Science ®Google Scholar
• Kathiramalainathan K , KaplanHL , RomachMKet al. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J. Clin. Psychopharmacol.20(4), 435–444 (2000).
   PubMed Web of Science ®Google Scholar
• Himmelsbach CK . The addiction liability of codeine. JAMA103(19), 1420 (1934).
   Google Scholar
• Babalonis S , LofwallMR , NuzzoPA , SiegelAJ , WalshSL. Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend.129(1–2), 116–124 (2013).
   PubMed Web of Science ®Google Scholar
• Stanley TH . The fentanyl story. J. Pain15(12), 1215–1226 (2014).
   PubMed Web of Science ®Google Scholar
• Bryson EO , SilversteinJH. Addiction and substance abuse in anesthesiology. Anesthesiology109(5), 905–917 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson L , SchwanerR. Transdermal fentanyl: pharmacology and toxicology. J. Med. Toxicol.5(4), 230–241 (2009).
   PubMedGoogle Scholar
• Suzuki J , El-HaddadS. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend.171, 107–116 (2017).
   PubMed Web of Science ®Google Scholar
• Duragesic (fentanyl transdermal system), package insert. Janssen Pharmaceutical Products, NJ, USA (2003).
   Google Scholar
• Fentanyl citrate injection, package insert. Akorn Inc, IL, USA (2012).
   Google Scholar
• Sverrisdóttir E , LundTM , OlesenAE , DrewesAM , ChristrupLL , KreilgaardM. A review of morphine and morphine-6-glucuronide’s pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. Eur. J. Pharm. Sci.74, 45–62 (2015).
   PubMed Web of Science ®Google Scholar
• AA Pharma Inc . Tramadol hydrochloride tablets [product monograph]. Auro Pharma Inc, ON, Canada (2018). https://pdf.hres.ca/dpd_pm/00045851.PDF
   Google Scholar
• Cardia L , CalapaiG , QuattroneDet al. Preclinical and clinical pharmacology of hydrocodone for chronic pain: a mini review. Front. Pharmacol.9, 1122 (2018).
   PubMed Web of Science ®Google Scholar
• Dilaudid oral solution and Dilaudid tablets (hydromorphone hydrochloride), package insert. Purdue Pharma L.P, CT, USA (2016).
   Google Scholar
• Kim HK , ConnorsNJ , Mazer-AmirshahiME. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin. Drug Saf.18(6), 465–475 (2019).
   PubMed Web of Science ®Google Scholar
• Concheiro M , ChesserR , PardiJ , CooperG. Postmortem toxicology of new synthetic opioids. Front. Pharmacol.9, 1210 (2018).
   PubMed Web of Science ®Google Scholar
• Drug Bank . www.drugbank.ca
   Google Scholar
• Jannetto PJ , HelanderA , GargU , JanisGC , GoldbergerB , KethaH. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union. Clin. Chem.65(2), 242–253 (2019).
   PubMed Web of Science ®Google Scholar
• Pchelintsev MV , GorbachevaEN , ZvartauEE. Simple methodology of assessment of analgesics’ addictive potential in mice. Pharmacol. Biochem. Behav.39(4), 873–876 (1991).
   PubMed Web of Science ®Google Scholar
• Greenwald MK . Behavioral economic analysis of drug preference using multiple choice procedure data. Drug Alcohol Depend.93(1–2), 103–110 (2008).
   PubMed Web of Science ®Google Scholar
• Butler SF , BlackRA , CassidyTA , DaileyTM , BudmanSH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct. J.8, 29 (2011).
   PubMed Web of Science ®Google Scholar
• Cicero TJ , EllisMS , ParadisA , OrtbalZ. Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals. Pharmacoepidemiol. Drug Saf.19(10), 1057–1063 (2010).
   PubMed Web of Science ®Google Scholar
• O’Donnell JK , HalpinJ , MattsonCL , GoldbergerBA , GladdenRM. Deaths involving fentanyl, fentanyl analogs and U-47700 – 10 states, July–December 2016. MMWR Morb. Mortal. Wkly Rep.66(43), 1197–1202 (2017).
   PubMed Web of Science ®Google Scholar
• Cardia L , CalapaiG , QuattroneDet al. Preclinical and clinical pharmacology of hydrocodone for chronic pain: a mini review. Front. Pharmacol.9, 1122 (2018).
   PubMed Web of Science ®Google Scholar
• Sindt JE , JenkinsonRH. Nonintravenous opioids. In: Pharmacology and Physiology for Anesthesia.2nd EditionHemmingsHC, EgamTD. ( Eds). Elsevier, PA, USA (2019).
   Google Scholar
• Elkader A , SprouleB. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet.44(7), 661–680 (2005).
   PubMed Web of Science ®Google Scholar
• Brown SM , HoltzmanM , KimT , KharaschED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology115(6), 1251–1260 (2011).
   PubMed Web of Science ®Google Scholar
• Vicencio-Rosas E , Pérez-GuilléMG , Flores-PérezC , Flores-PérezJ , Trujillo-JiménezF , Chávez-PachecoJL. Buprenorphine and pain treatment in pediatric patients: an update. J. Pain Res.11, 549–559 (2018).
   PubMed Web of Science ®Google Scholar
• Oyler JM , ConeEJ , JosephREJr , HuestisMA. Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol.24(7), 530–535 (2000).
   PubMed Web of Science ®Google Scholar
• Thorn CF , KleinTE , AltmanRB. Codeine and morphine pathway. Pharmacogenet. Genomics.19(7), 556–558 (2009).
   PubMed Web of Science ®Google Scholar
• Cone EJ , HeitHA , CaplanYH , GourlayD. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J. Anal. Toxicol.30(1), 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Cone EJ , CaplanYH , MoserF , RobertT , BlackD. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J. Anal. Toxicol.32(4), 319–323 (2008).
   PubMed Web of Science ®Google Scholar
• Christrup LL . Morphine metabolites. Acta Anaesthesiol. Scand.41(1 Pt 2), 116–122 (1997).
   PubMed Web of Science ®Google Scholar
• Projean D , MorinPE , TuTM , DucharmeJ. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica33(8), 841–854 (2003).
   PubMed Web of Science ®Google Scholar
• Coffman BL , RiosGR , KingCD , TephlyTR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos.25(1), 1–4 (1997).
   PubMed Web of Science ®Google Scholar
• Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium . Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther.91(2), 321–326 (2012).
   PubMed Web of Science ®Google Scholar
• Kamendulis LM , BrzezinskiMR , PindelEV , BosronWF , DeanRA. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther.279(2), 713–717 (1996).
   PubMed Web of Science ®Google Scholar
• Rady JJ , AksuF , FujimotoJM. The heroin metabolite, 6-monoacetylmorphine, activates delta opioid receptors to produce antinociception in Swiss-Webster mice. J. Pharmacol. Exp. Ther.268(3), 1222–1231 (1994).
   PubMed Web of Science ®Google Scholar
• Labroo RB , PaineMF , ThummelKE , KharaschED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy and drug interactions. Drug Metab. Dispos.25(9), 1072–1080 (1997).
   PubMed Web of Science ®Google Scholar
• Navani DM , YoburnBC. In vivo activity of norhydrocodone: an active metabolite of hydrocodone. J. Pharmacol. Exp. Ther.347(2), 497–505 (2013).
   PubMed Web of Science ®Google Scholar
• Lalovic B , KharaschE , HofferC , RislerL , Liu-ChenL-Y , ShenDD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther.79(5), 461–479 (2006).
   PubMed Web of Science ®Google Scholar
• Lalovic B , PhillipsB , RislerLL , HowaldW , ShenDD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos.32(4), 447–454 (2004).
   PubMed Web of Science ®Google Scholar
• Huddart R , ClarkeM , AltmanRB , KleinTE. PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet. Genomics28(10), 230–237 (2018).
   PubMed Web of Science ®Google Scholar
• Samer CF , DaaliY , WagnerMet al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br. J. Pharmacol.160(4), 907–918 (2010).
   PubMed Web of Science ®Google Scholar
• Volpe DA , McmahonTobin GA , MellonRDet al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul. Toxicol. Pharmacol.59(3), 385–390 (2011).
   PubMed Web of Science ®Google Scholar
• Gauvin DV , MccombM , CodeR , DaltonJA , BairdTJ. Abuse liability assessment of hydrocodone under current draft regulatory guidelines. J. Pharmacol. Toxicol. Meth.75, 118–129 (2015).
   PubMed Web of Science ®Google Scholar
• Zacny JP , GutierrezS. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend.101(1–2), 107–114 (2009).
   PubMed Web of Science ®Google Scholar
• Quinn DI , WodakA , DayRO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin. Pharmacokinet.33(5), 344–400 (1997).
   PubMed Web of Science ®Google Scholar
• Adams EH , BreinerS , CiceroTJet al. A comparison of the abuse liability of tramadol, NSAIDs and hydrocodone in patients with chronic pain. J. Pain Symptom Manage.31(5), 465–476 (2006).
   PubMed Web of Science ®Google Scholar
• Zacny JP , GutierrezS , BolbolanSA. Profiling the subjective, psychomotor and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug Alcohol Depend.78(3), 243–252 (2005).
   PubMed Web of Science ®Google Scholar
• Mazer-Amirshahi M , MullinsPM , RasoolyI , VanDen Anker J , PinesJM. Rising opioid prescribing in adult U.S. emergency department visits: 2001–2010. Acad. Emerg. Med.21(3), 236–243 (2014).
   PubMed Web of Science ®Google Scholar
• Mazer-Amirshahi M , LadkanyD , MullinsPMet al. Trends in and predictors of hydromorphone administration in US emergency departments (2007–2014). J. Opioid Manag.14(4), 265–272 (2018).
   PubMedGoogle Scholar
• Chang AK , BijurPE , MeyerRH , KennyMK , SolorzanoC , GallagherEJ. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial. Ann. Emerg. Med.48(2), 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Chang AK , BijurPE , NapolitanoA , LupowJ , GallagherEJ. Two milligrams i.v. hydromorphone is efficacious for treating pain but is associated with oxygen desaturation. J. Opioid Manag.5(2), 75–80 (2009).
   PubMedGoogle Scholar
• Coda B , TanakaA , JacobsonRC , DonaldsonG , ChapmanCR. Hydromorphone analgesia after intravenous bolus administration. Pain71(1), 41–48 (1997).
   PubMed Web of Science ®Google Scholar
• Mazer-Amirshahi M , MotovS , NelsonLS. Hydromorphone use for acute pain: misconceptions, controversies and risks. J. Opioid Manag.14(1), 61–71 (2018).
   PubMedGoogle Scholar
• Vallner JJ , StewartJT , KotzanJA , KirstenEB , HonigbergIL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J. Clin. Pharmacol.21(4), 152–156 (1981).
   PubMed Web of Science ®Google Scholar
• Dasgupta N , FreifeldC , BrownsteinJSet al. Crowdsourcing black market prices for prescription opioids. J. Med. Internet Res.15(8), e178 (2013).
   PubMed Web of Science ®Google Scholar
• Abi-Aad KR , DerianA. Hydromorphone. In: StatPearls.StatPearls Publishing LLC, FL, USA (2020).
   Google Scholar
• Jasinski DR . Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Drug Addiction I.MartinWR. ( Ed.) Springer, Berlin, Germany, 197–258 (1977).
   Google Scholar
• Hill JL , ZacnyJP. Comparing the subjective, psychomotor and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology152(1), 31–39 (2000).
   PubMed Web of Science ®Google Scholar
• Walsh SL , NuzzoPA , LofwallMR , HoltmanJR Jr.. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend.98(3), 191–202 (2008).
   PubMed Web of Science ®Google Scholar
• Cicero TJ , EllisMS , ParadisA , OrtbalZ. Role of key informants and direct patient interviews in epidemiological studies of substance abuse. Pharmacoepidemiol. Drug Saf.20(3), 308–312 (2011).
   PubMed Web of Science ®Google Scholar
• Butler SF , McnaughtonEC , BlackRA , CassidyTA. Evaluation of the relative abuse of an OROS extended-release hydromorphone HCI product: results from 3 postmarket surveillance studies. Clin. J. Pain34(7), 618–628 (2018).
   PubMed Web of Science ®Google Scholar
• Silverman M , SlaterJ , JandocR , KoivuS , GargAX , WeirMA. Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study. Lancet Infect. Dis.20(4), 487–497 (2020).
   PubMed Web of Science ®Google Scholar
• Atluri S , SudarshanG , ManchikantiL. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Phys.17(2), E119–E128 (2014).
   PubMed Web of Science ®Google Scholar
• Luch A . Molecular, Clinical and Environmental Toxicology: Volume 1: Molecular Toxicology.LuchA ( Ed.)., Birkhäuser, Basel, Switzerland (2009).
   Google Scholar
• Pathan H , WilliamsJ. Basic opioid pharmacology: an update. Br. J. Pain6(1), 11–16 (2012).
   PubMedGoogle Scholar
• Morphine sulfate injection, package insert. Hospira, Inc, IL, USA (2011).
   Google Scholar
• Smith HS . The metabolism of opioid agents and the clinical impact of their active metabolites. Clin. J. Pain27(9), 824–838 (2011).
   PubMed Web of Science ®Google Scholar
• Bodd E , JacobsenD , LundE , RipelA , MørlandJ , Wiik-LarsenE. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum. Exp. Toxicol.9(5), 317–321 (1990).
   PubMed Web of Science ®Google Scholar
• Wightman R , PerroneJ , PortelliI , NelsonL. Likeability and abuse liability of commonly prescribed opioids. J. Med. Toxicol.8(4), 335–340 (2012).
   PubMedGoogle Scholar
• Cicero TJ , EllisMS , KasperZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol. Drug Saf.26(1), 56–62 (2017).
   PubMed Web of Science ®Google Scholar
• Withington DE , PatrickJA , ReynoldsF. Histamine release by morphine and diamorphine in man. Anaesthesia48(1), 26–29 (2007).
   Google Scholar
• Pöyhiä R , VainioA , KalsoE. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J. Pain Symptom Manage.8(2), 63–67 (1993).
   PubMed Web of Science ®Google Scholar
• Gallego AO , OrdóñezGallego A , GonzálezBarón M , EspinosaArranz E. Oxycodone: a pharmacological and clinical review. Clin. Transl. Oncol.9(5), 298–307 (2007).
   PubMed Web of Science ®Google Scholar
• Boström E , SimonssonUSH , Hammarlund-UdenaesM. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos.34(9), 1624–1631 (2006).
   PubMed Web of Science ®Google Scholar
• Boström E , Hammarlund-UdenaesM , SimonssonUSH. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology108(3), 495–505 (2008).
   PubMed Web of Science ®Google Scholar
• Schaefer CP , TomeME , DavisTP. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS14(1), 32 (2017).
   PubMedGoogle Scholar
• Okura T , HattoriA , TakanoYet al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab. Dispos.36(10), 2005–2013 (2008).
   PubMed Web of Science ®Google Scholar
• Vander Weele CM , Porter-StranskyKA , MabroukOSet al. Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. Eur. J. Neurosci.40(7), 3041–3054 (2014).
   PubMed Web of Science ®Google Scholar
• Remillard D , KayeAD , McanallyH. Oxycodone’s unparalleled addictive potential: is it time for a moratorium?Curr. Pain Headache Rep.23(2), 15 (2019).
   PubMed Web of Science ®Google Scholar
• Zacny JP , GutierrezS. Characterizing the subjective, psychomotor and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology170(3), 242–254 (2003).
   PubMed Web of Science ®Google Scholar
• Zacny JP , LichtorSA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology196(1), 105–116 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenblum A , ParrinoM , SchnollSHet al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend.90(1), 64–71 (2007).
   PubMed Web of Science ®Google Scholar
• Stoops WW , LofwallMR , NuzzoPA , CraigLB , SiegelAJ , WalshSL. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology223(4), 427–438 (2012).
   PubMed Web of Science ®Google Scholar
• Dunn KE , BergeriaCL , HuhnAS , StrainEC. A systematic review of laboratory evidence for the abuse potential of tramadol in humans. Front. Psychiatry10, 704 (2019).
   PubMed Web of Science ®Google Scholar
• Skipper GE , FletcherC , Rocha-JuddR , BraseD. Tramadol abuse and dependence among physicians. JAMA292(15), 1818–1819 (2004).
   PubMed Web of Science ®Google Scholar
• Salm-Reifferscheidt L . Tramadol: africa’s opioid crisis. Lancet391(10134), 1982–1983 (2018).
   PubMed Web of Science ®Google Scholar
• Bassiony MM , SalahEl-Deen GM , YousefUet al. Adolescent tramadol use and abuse in Egypt. Am. J. Drug Alcohol Abuse41(3), 206–211 (2015).
   PubMed Web of Science ®Google Scholar
• Mattick RP , BreenC , KimberJ , DavoliM. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev.2(3), CD002209 (2009).
   Google Scholar
• Dolophine (Methadone), package insert. Roxane Laboratories, Inc, OH, USA (2006).
   Google Scholar
• Kim HK , NelsonLS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin. Drug Saf.14(7), 1137–1146 (2015).
   PubMed Web of Science ®Google Scholar
• Dahan A , YassenA , RombergRet al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br. J. Anaesth.96(5), 627–632 (2006).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , AloisiAM , DahanAet al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract.10(5), 428–450 (2010).
   PubMed Web of Science ®Google Scholar
• Subutex, package insert . Reckitt Benckiser Healthcare (UK) Ltd, Hull, UK (2002).
   Google Scholar
• Lofwall MR , WalshSL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J. Addict. Med.8(5), 315–326 (2014).
   PubMed Web of Science ®Google Scholar